Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
Clinigen specialises in managed access programmes which provide medicines to people in need where the product does not have regulatory sign-off in the local jurisdiction
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects
Sareum has partnered with Sierra Oncology to advance the company's Checkpoint kinase 1 inhibitor
The definitive results of the company's pharmacokinetic study will be used to guide phase III clinical assessments of lead product, MED2002
The company has driven iclaprim to the verge of regulatory approval after completing two successful phase III clinical trials
Based on current predictions, the final analysis of overall survival data from the phase III study is expected in the second-half of the year rather than the first
The regenerative medicines specialist will use the proceeds from the four-year credit facility to fund the commercialisation of its graft versus host disease treatment, which was successful in a phase III clinical trial.
Richard Douglas was senior vice president of corporate development and corporate officer at Genzyme Corporation from 1989 until its sale to Sanofi in 2011
Two companies, three wells
Drilling down into the world of E&P as we keep tabs of on the gushers and dusters
A look at some early analyst views in the City
The bookmakers have been put under the microscope, while Shell has been downgraded.